Cargando…
Real-world data of six patients with atypical hemolytic uremic syndrome switched to ravulizumab
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8445866/ https://www.ncbi.nlm.nih.gov/pubmed/34274988 http://dx.doi.org/10.1007/s00467-021-05203-8 |
| _version_ | 1784568744810381312 |
|---|---|
| author | Ehren, Rasmus Habbig, Sandra |
| author_facet | Ehren, Rasmus Habbig, Sandra |
| author_sort | Ehren, Rasmus |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8445866 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Springer Berlin Heidelberg |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-84458662021-10-01 Real-world data of six patients with atypical hemolytic uremic syndrome switched to ravulizumab Ehren, Rasmus Habbig, Sandra Pediatr Nephrol Letter to the Editors Springer Berlin Heidelberg 2021-07-17 2021 /pmc/articles/PMC8445866/ /pubmed/34274988 http://dx.doi.org/10.1007/s00467-021-05203-8 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Letter to the Editors Ehren, Rasmus Habbig, Sandra Real-world data of six patients with atypical hemolytic uremic syndrome switched to ravulizumab |
| title | Real-world data of six patients with atypical hemolytic uremic syndrome switched to ravulizumab |
| title_full | Real-world data of six patients with atypical hemolytic uremic syndrome switched to ravulizumab |
| title_fullStr | Real-world data of six patients with atypical hemolytic uremic syndrome switched to ravulizumab |
| title_full_unstemmed | Real-world data of six patients with atypical hemolytic uremic syndrome switched to ravulizumab |
| title_short | Real-world data of six patients with atypical hemolytic uremic syndrome switched to ravulizumab |
| title_sort | real-world data of six patients with atypical hemolytic uremic syndrome switched to ravulizumab |
| topic | Letter to the Editors |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8445866/ https://www.ncbi.nlm.nih.gov/pubmed/34274988 http://dx.doi.org/10.1007/s00467-021-05203-8 |
| work_keys_str_mv | AT ehrenrasmus realworlddataofsixpatientswithatypicalhemolyticuremicsyndromeswitchedtoravulizumab AT habbigsandra realworlddataofsixpatientswithatypicalhemolyticuremicsyndromeswitchedtoravulizumab |